Go to
current issue
-
Cancer care in Sri Lanka amid financial crisis Lancet Oncol. (IF 51.1) Pub Date : 2023-09-21 Manjulika Das
Abstract not available
-
US Government convenes first National Cancer Plan stakeholders' meeting Lancet Oncol. (IF 51.1) Pub Date : 2023-09-14 Bryant Furlow
Abstract not available
-
The UK rejoins Horizon Europe Lancet Oncol. (IF 51.1) Pub Date : 2023-09-14 Talha Khan Burki
Abstract not available
-
Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study Lancet Oncol. (IF 51.1) Pub Date : 2023-09-14 Niels W C J van de Donk, Monique C Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Annemiek Broijl, Wilfried W H Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H J van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Wida Razawy, Paola Tacchetti, Katia Mancuso, Trine Silkjaer, Jo Caers, Pellegrino Musto
Background Primary plasma cell leukaemia is a rare and aggressive plasma cell disorder with a poor prognosis. The aim of the EMN12/HOVON-129 study was to improve the outcomes of patients with primary plasma cell leukaemia by incorporating carfilzomib and lenalidomide in induction, consolidation, and maintenance therapy. Methods The EMN12/HOVON-129 study is a non-randomised, phase 2, multicentre study
-
Cancer advocates call for national cancer body in South Africa Lancet Oncol. (IF 51.1) Pub Date : 2023-09-14 Munyaradzi Makoni
Abstract not available
-
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial Lancet Oncol. (IF 51.1) Pub Date : 2023-09-12 Fred Saad, Noel W Clarke, Mototsugu Oya, Neal Shore, Giuseppe Procopio, João Daniel Guedes, Cagatay Arslan, Niven Mehra, Francis Parnis, Emma Brown, Friederike Schlürmann, Jae Young Joung, Mikio Sugimoto, Oliver Sartor, Yu-Zhen Liu, Christian Poehlein, Laura Barker, Paula Michelle del Rosario, Andrew J Armstrong
Background PROpel met its primary endpoint showing statistically significant improvement in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus abiraterone in patients with first-line metastatic castration-resistant prostate cancer (mCRPC) unselected by homologous recombination repair mutation (HRRm) status, with benefit observed in all prespecified subgroups.
-
Comedians stand up to cancer at the Edinburgh Fringe Lancet Oncol. (IF 51.1) Pub Date : 2023-09-12 Peter Ranscombe
Abstract not available
-
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial Lancet Oncol. (IF 51.1) Pub Date : 2023-09-11 S Lot Aronson, Marta Lopez-Yurda, Simone N Koole, Jules H Schagen van Leeuwen, Hendrik W R Schreuder, Ralph H M Hermans, Ignace H J T de Hingh, Mignon D J M van Gent, Henriëtte J G Arts, Maaike A P C van Ham, Peter A van Dam, Peter Vuylsteke, Arend G J Aalbers, Victor J Verwaal, Koen K Van de Vijver, Neil K Aaronson, Gabe S Sonke, Willemien J van Driel
Background The OVHIPEC-1 trial previously showed that the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery resulted in improved progression-free and overall survival compared with cytoreductive surgery alone at 4·7 years of follow-up in patients with stage III epithelial ovarian cancer who were ineligible for primary cytoreduction. We report the final
-
Africa reaffirms commitments to eliminate cervical cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-09-08 Munyaradzi Makoni
Abstract not available
-
Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2023-09-08 Robert W Mutter, Sharmila Giri, Briant F Fruth, Nicholas B Remmes, Judy C Boughey, Christin A Harless, Kathryn J Ruddy, Lisa A McGee, Arslan Afzal, Robert W Gao, Dean A Shumway, Tamara Z Vern-Gross, Hector R Villarraga, Stephanie L Kenison, Yixiu Kang, William W Wong, Bradley J Stish, Kenneth W Merrell, Elizabeth S Yan, Sean S Park, Carlos E Vargas
Background Proton therapy is under investigation in breast cancer as a strategy to reduce radiation exposure to the heart and lungs. So far, studies investigating proton postmastectomy radiotherapy (PMRT) have used conventional fractionation over 25–28 days, but whether hypofractionated proton PMRT is feasible is unclear. We aimed to compare conventional fractionation and hypofractionation in patients
-
Combination immunotherapy in chemotherapy in gastric cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-09-01 Kazuhiro Shiraishi, Shun Yamamoto, Ken Kato
Abstract not available
-
First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial Lancet Oncol. (IF 51.1) Pub Date : 2023-09-01 Samuel L Cytryn, Ryan H Moy, Darren Cowzer, Ronak H Shah, Joanne F Chou, Smita S Joshi, Geoffrey Y Ku, Steven B Maron, Avni Desai, Jessica Yang, Ryan Sugarman, Devika Rao, Zoe Goldberg, Carmelina Charalambous, Maria Lapshina, Ariel Antoine, Fiona Socolow, Nikhil Trivedi, Marinela Capanu, Hans Gerdes, Yelena Y Janjigian
Background The addition of nivolumab to chemotherapy improves survival in patients with advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) adenocarcinoma; however, outcomes remain poor. We assessed the safety and activity of regorafenib in combination with nivolumab and chemotherapy in the first-line treatment of advanced oesophagogastric adenocarcinoma. Methods This
-
Avoidable mortality in the UK unlikely to change soon Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29
Abstract not available
-
Tumor Treating Fields therapy could potentiate immunotherapy in non-small-cell lung cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Dean A Fennell
Abstract not available
-
SERDs for primary breast cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Masakazu Toi, Tomoyuki Aruga
Abstract not available
-
Combined gene therapies for high-grade glioma Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Joshua D Bernstock, Alexander Ling, E Antonio Chiocca
Abstract not available
-
Gauging radiotherapy resources in South America and the Caribbean Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Kellie Alleyne-Mike
Abstract not available
-
Precision medicine for children with cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Ian F Tannock
Abstract not available
-
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Elif Hindié
Abstract not available
-
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy – Author's reply Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Binghe Xu
Abstract not available
-
Incorporating absolute effects to enrich interpretation of findings from meta-analyses Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Jing Wu, Shitong Xie, Xiaoning He, Tianqi Hong, Liang Yao
Abstract not available
-
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Claire Petit, Jean-Pierre Pignon, Pierre Blanchard
Abstract not available
-
Cancer research funding and care in the Philippines: gaps and ways forward Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Katrina T Feliciano, Ullma Carmelene Demfre P Lindo, Althea Nicole P Tanedo, Dianne Camille A Gaspar, Jake Bryan S Cortez
Abstract not available
-
Correction to Lancet Oncology 2023; 24: 855–67 Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29
Abstract not available
-
UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver new anti-cancer therapies Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Mark P Lythgoe, Richard Sullivan, Sarah Blagden
Abstract not available
-
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Ticiana Leal, Rupesh Kotecha, Rodryg Ramlau, Li Zhang, Janusz Milanowski, Manuel Cobo, Jaromir Roubec, Lubos Petruzelka, Libor Havel, Sujith Kalmadi, Jeffrey Ward, Zoran Andric, Thierry Berghmans, David E Gerber, Goetz Kloecker, Rajiv Panikkar, Joachim Aerts, Angelo Delmonte, Miklos Pless, Richard Greil, Corey Langer
Background Tumor Treating Fields (TTFields) are electric fields that disrupt processes critical for cancer cell survival, leading to immunogenic cell death and enhanced antitumour immune response. In preclinical models of non-small-cell lung cancer, TTFields amplified the effects of chemotherapy and immune checkpoint inhibitors. We report primary results from a pivotal study of TTFields therapy in
-
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Usha Menon, Aleksandra Gentry-Maharaj, Matthew Burnell, Andy Ryan, Naveena Singh, Ranjit Manchanda, Jatinderpal K Kalsi, Robert Woolas, Rupali Arora, Laura Casey, Anne Dawnay, Aarti Sharma, Karin Williamson, Sophia Apostolidou, Lesley Fallowfield, Alistair J McGuire, Stuart Campbell, Steven J Skates, Ian J Jacobs, Mahesh K B Parmar
Background In UKCTOCS, there was a decrease in the diagnosis of advanced stage tubo-ovarian cancer but no reduction in deaths in the multimodal screening group compared with the no screening group. Therefore, we did exploratory analyses of patients with high-grade serous ovarian cancer to understand the reason for the discrepancy. Methods UKCTOCS was a 13-centre randomised controlled trial of screening
-
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Sara A Hurvitz, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, Isabel Blancas, José Luis Alonso-Romero, Aleksandr Vasiliev, Hryhoriy Adamchuk, Marcelo Salgado, Denise A Yardley, Oleksandr Berzoy, Pilar Zamora-Auñón, David Chan, Gonzalo Spera, Cloris Xue, Erika Ferreira, Tanja Badovinac Crnjevic, Pablo Diego Pérez-Moreno, Vanesa López-Valverde, Jutta Steinseifer, Peter A Fasching
Background The development of more potent selective oestrogen receptor antagonists and degraders (SERDs) that can be orally administered could help to address the limitations of current endocrine therapies. We report the primary and final analyses of the coopERA Breast Cancer study, designed to test whether giredestrant, a highly potent, non-steroidal, oral SERD, would show a stronger anti-proliferative
-
Combined cytotoxic and immune-stimulatory gene therapy for primary adult high-grade glioma: a phase 1, first-in-human trial Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Yoshie Umemura, Daniel Orringer, Larry Junck, Maria L Varela, Molly E J West, Syed M Faisal, Andrea Comba, Jason Heth, Oren Sagher, Denise Leung, Aaron Mammoser, Shawn Hervey-Jumper, Daniel Zamler, Viveka N Yadav, Patrick Dunn, Wajd Al-Holou, Todd Hollon, Michelle M Kim, Daniel R Wahl, Sandra Camelo-Piragua, Pedro R Lowenstein
Background High-grade gliomas have a poor prognosis and do not respond well to treatment. Effective cancer immune responses depend on functional immune cells, which are typically absent from the brain. This study aimed to evaluate the safety and activity of two adenoviral vectors expressing HSV1-TK (Ad-hCMV-TK) and Flt3L (Ad-hCMV-Flt3L) in patients with high-grade glioma. Methods In this dose-finding
-
Financial hardship in families of children or adolescents with cancer: a systematic literature review Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Julie Ritter, Savannah Allen, Phillip D Cohen, Andrés Felipe Fajardo, Kelsey Marx, Patrícia Loggetto, Carmen Auste, Hedley Lewis, Karla Emília de Sá Rodrigues, Sharmeen Hussain, Ayomide Omotola, Nancy S Bolous, Harsha Thirumurthy, Beverley M Essue, Eva Steliarova-Foucher, I-Chan Huang, Filip Meheus, Nickhill Bhakta
Financial hardship in childhood cancer contributes to poor health outcomes and global disparities in survival, but the extent of the financial burden on families is not yet fully understood. We systematically reviewed financial hardship prevalence and individual components characterising financial hardship across six domains (medical, non-medical, and indirect costs, financial strategies, psychosocial
-
Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 May Elbanna, Yaroslav Pynda, Oleksandr Kalinchuk, Arthur Rosa, May Abdel-Wahab
The inequitable access to radiotherapy globally is a complex undertaking that will require sustained work identifying gaps and mobilising efforts to resolve. The purpose of this review is to identify gaps and needs in radiotherapy in Latin America and the Caribbean. Data from 41 countries in Latin America and the Caribbean on teletherapy megavoltage units and brachytherapy resources were extracted
-
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU? Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Allan Cramer, Freja K H Sørup, Hanne R Christensen, Tonny S Petersen, Kristian Karstoft
As of April, 2023, 23 accelerated approvals for cancer indications granted by the US Food and Drug Administration (FDA) since 1992 have been withdrawn from the US market, with 17 (74%) of 23 withdrawn in the past 3 years. The marketing authorisation status of these indications in the EU has not been reported. A review of relevant documents from the FDA and the European Medicines Agency (EMA) was done
-
Choriocarcinoma masquerading as pulmonary embolism in a patient with a history of tuberculosis Lancet Oncol. (IF 51.1) Pub Date : 2023-08-29 Guan-Lin Dai, Yi-Cheng Wu, Dan-Qing Wang
Abstract not available
-
Cancer care after the wildfires in Hawai'i Lancet Oncol. (IF 51.1) Pub Date : 2023-08-24 Manjulika Das
Abstract not available
-
Medically assisted dying and cancer: a complex issue Lancet Oncol. (IF 51.1) Pub Date : 2023-08-17 Kathryn Senior
Abstract not available
-
NICE approval of AI technology for radiotherapy contour planning Lancet Oncol. (IF 51.1) Pub Date : 2023-08-17 Emma Wilkinson
Abstract not available
-
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial Lancet Oncol. (IF 51.1) Pub Date : 2023-08-14 Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Miranda Gogishvili, Marina Nechaeva, Michael Schenker, Irfan Cicin, Gwo Fuang Ho, Yaroslav Kulyaba, Kasimova Zyuhal, Roxana-Ioana Scheusan, Marina Chiara Garassino, Xuanyao He, Manika Kaul, Emmanuel Okoye, Yuntong Li, Siyu Li, Jean-Francois Pouliot, Petra Rietschel
Background Cemiplimab provided significant survival benefit to patients with advanced non-small-cell lung cancer with PD-L1 tumour expression of at least 50% and no actionable biomarkers at 1-year follow-up. In this exploratory analysis, we provide outcomes after 35 months' follow-up and the effect of adding chemotherapy to cemiplimab at the time of disease progression. Methods EMPOWER-Lung 1 was a
-
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm Lancet Oncol. (IF 51.1) Pub Date : 2023-08-10 Bryant Furlow
Abstract not available
-
Gynaecological cancer waiting times in Northern Ireland Lancet Oncol. (IF 51.1) Pub Date : 2023-08-10 Priya Venkatesan
Abstract not available
-
Improved cancer coverage for firefighters in Western Australia Lancet Oncol. (IF 51.1) Pub Date : 2023-08-10 Elizabeth Gourd
Abstract not available
-
A legacy of war: cancer care fragmentation in Iraq Lancet Oncol. (IF 51.1) Pub Date : 2023-08-10 Vijay Shankar Balakrishnan
Abstract not available
-
WHO's ninth report on the global tobacco epidemic Lancet Oncol. (IF 51.1) Pub Date : 2023-08-03 Udani Samarasekera
Abstract not available
-
Italy helps in Lebanon's cancer drug crisis Lancet Oncol. (IF 51.1) Pub Date : 2023-08-03 Manjulika Das
Abstract not available
-
Climate change and skin cancer: urgent call for action Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01
Abstract not available
-
2020 cancer incidence data in the USA reveal effects of the COVID-19 pandemic Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Julie S Townsend
Abstract not available
-
Artificial intelligence for breast cancer screening: breathtaking results and a word of caution Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Nereo Segnan, Antonio Ponti
Abstract not available
-
Establishing a Lancet Oncology Commission on the humanitarian crisis of cancer Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Gary Rodin, Mac Skelton, Nirmala Bhoo-Pathy, Omar Dewachi, Madeline Li, Dario Trapani, Elizabeth Smyth, Matthew Banegas, Naveen Salins, Karla Unger-Saldaña, Camilla Zimmermann, Richard Sullivan
Abstract not available
-
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Rahul Jena, Rami Issa, Matthew Perry
Abstract not available
-
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Alexandre R Zlotta, Katherine Lajkosz, Jason A Efstathiou
Abstract not available
-
Correction to Lancet Oncol 2023; 24: 611–23 Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01
Abstract not available
-
Correction to Lancet Oncol 2023; 24: 868–80 Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01
Abstract not available
-
ICGC ARGO precision medicine: genomic profiling-informed prediction of immunotherapy response in two patients with metastatic head and neck squamous cell carcinoma Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Riccardo Nocini, Luca Tondulli, Consuelo D’Ambrosio, Claudio Luchini, Andrew V Biankin, Raffaella Casolino, Aldo Scarpa
Abstract not available
-
The post-truth anti-science era: what and who can we trust? | Laura Hart, Risk and adaptation in a cancer cluster town, Rutgers University Press (2023), p. 176, ISBN: 9781978823532 Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Jules Morgan
Abstract not available
-
Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Xuesong Han, Nuo Nova Yang, Leticia Nogueira, Changchuan Jiang, Nikita Sandeep Wagle, Jingxuan Zhao, Kewei Sylvia Shi, Qinjin Fan, Elizabeth Schafer, K Robin Yabroff, Ahmedin Jemal
Background The emergence of COVID-19 disrupted health care, with consequences for cancer diagnoses and outcomes, especially for early stage diagnoses, which generally have favourable prognoses. We aimed to examine nationwide changes in adult cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic by cancer type and key sociodemographic factors in the USA. Methods In this
-
Radiotherapy resources in Brazil (RT2030): a comprehensive analysis and projections for 2030 Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Arthur Accioly Rosa, Cecília Félix Penido Mendes de Sousa, Leonardo Cunha Furbino Pimentel, Homero Lavieri Martins, Fabio Ynoe Moraes, Gustavo Nader Marta, Marcus Simões Castilho
Background The demand for radiotherapy in Brazil is unfulfilled, and the scarcity of data on the national network hampers the development of effective policies. We aimed to evaluate the current situation, estimate demands and requirements, and provide an action plan to ensure access to radiotherapy for those in need by 2030. Methods The Brazilian Society for Radiation Oncology created a task force
-
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Shubham Pant, Martin Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A Reardon, Christophe Massard, Anna Minchom, Iwona Lugowska, Omar Carranza, Dirk Arnold, Martin Gutierrez, Helen Winter, Kim Stuyckens, Lauren Crow, Saltanat Najmi, Constance Hammond, Shibu Thomas, Sharon Wilks
Background FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. Methods The
-
Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Kristina Lång, Viktoria Josefsson, Anna-Maria Larsson, Stefan Larsson, Charlotte Högberg, Hanna Sartor, Solveig Hofvind, Ingvar Andersson, Aldana Rosso
Background Retrospective studies have shown promising results using artificial intelligence (AI) to improve mammography screening accuracy and reduce screen-reading workload; however, to our knowledge, a randomised trial has not yet been conducted. We aimed to assess the clinical safety of an AI-supported screen-reading protocol compared with standard screen reading by radiologists following mammography
-
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 David Pasquier, Luc Bidaut, Daniela Elena Oprea-Lager, Nandita M deSouza, David Krug, Laurence Collette, Wolfgang Kunz, Yazid Belkacemi, Maria Grazia Bau, Caroline Caramella, Lioe-Fee De Geus-Oei, Alex De Caluwé, Christophe Deroose, Olivier Gheysens, Ken Herrmann, Isabelle Kindts, Michalis Kontos, Sherko Kümmel, Barbro Linderholm, Egesta Lopci, Frédéric E Lecouvet
Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from
-
National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Michelle M Kim, Minesh P Mehta, DeeDee K Smart, Patricia S Steeg, Julie A Hong, Michael G Espey, Pataje G Prasanna, Laura Crandon, Christine Hodgdon, Niki Kozak, Terri S Armstrong, Aki Morikawa, Nicole Willmarth, Kirk Tanner, Adrienne Boire, Melanie Hayden Gephart, Kim A Margolin, Jona Hattangadi-Gluth, Hussein Tawbi, Daniel M Trifiletti, Mansoor M Ahmed
Brain metastases are an increasing global public health concern, even as survival rates improve for patients with metastatic disease. Both metastases and the sequelae of their treatment are key determinants of the inter-related priorities of patient survival, function, and quality of life, mandating a multidimensional approach to clinical care and research. At a virtual National Cancer Institute Workshop
-
Metastatic seminoma masquerading as sarcoidosis Lancet Oncol. (IF 51.1) Pub Date : 2023-08-01 Kevin E Shopsowitz, Xiu Qing Wang, Maryam Soleimani, Monika Hudoba, Luke Y C Chen, Eric McGinnis
Abstract not available
更新日期：2023-09-23
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号